Maxalt Lyo

Rizatriptan, the active ingredient in Maxalt Lyo, is a triptan presented as a oral lyophilisate tablet for oral use. It treats acute migraine attacks in adults, providing rapid relief of headache and associated symptoms.\n\nGNH India supplies Maxalt Lyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rizatriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute treatment of migraine.\n\nMigraine without aura: reduces headache intensity and associated nausea.\nMigraine with aura: alleviates both headache and visual or sensory aura symptoms.\nAcute migraine attacks: provides rapid relief of pain, photophobia and phonophobia.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.\n\nCommon Side Effects:\n- Taste disturbance or bitter taste\n- Nausea or abdominal discomfort\n- Dizziness or light‑headedness\n- Fatigue or drowsiness\n- Paresthesia (tingling)\n- Dry mouth\n\nSerious or Rare Side Effects:\n- Chest pain or tightness (possible coronary vasospasm)\n- Severe allergic reaction (anaphylaxis, rash, swelling)\n- Serotonin syndrome when combined with serotonergic agents\n- Hypertension or sudden increase in blood pressure\n- Cardiac arrhythmias\n- Ischemic stroke (very rare).

Before prescribing Rizatriptan, clinicians should evaluate cardiovascular risk and contraindications.\n\nAssess cardiovascular history: avoid in patients with coronary artery disease or uncontrolled hypertension.\nReview concomitant serotonergic drugs: monitor for serotonin syndrome.\nAvoid in patients with a history of hemiplegic or basilar migraine.\nCheck for drug interactions: especially MAO inhibitors and ergot derivatives.\nEducate patients on recognizing chest discomfort and seeking immediate care.\nStore at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Rizatriptan can interact with several medication classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- MAO inhibitors: increased risk of serotonin syndrome.\n- Other triptans or ergot alkaloids: additive vasoconstriction.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated Rizatriptan levels.\n- SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity.\n- Monoamine oxidase inhibitors (within 14 days): risk of severe reactions.\n\nModerate Interactions (Monitor Closely):\n- Antihypertensive agents: possible additive blood pressure effects.\n- NSAIDs: may increase risk of gastrointestinal irritation.\n- Oral contraceptives: monitor for reduced efficacy.\n- Antihistamines: may enhance dizziness.\n- Alcohol: can exacerbate central nervous system side effects.